nexi-001
spdr s&p biotech,ishares biotechnology,neximmune
['aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', '$ibb', '$xbi']
$nexi neximmune reveals encouraging early results for nexi-001 in phase 1 trial for relapsed/refractory post allo-hsct aml at asco 2023 annual meeting more info: $xbi $ibb $xph $pph 
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt